Industry: Pharmaceuticals, Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based publicly held biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar’s oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme which is currently being tested in a Phase I clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D which has been clinically tested in a number of solid tumor types. ( www.cougarbiotechnology.com )
Cougar Biotechnology , Inc.
10990 Wilshire Blvd. Suite 1200
Los Angeles, California 90024
USA
Tel: (310) 943-8040
Fax: (310) 943-8059